Pediatrix Medical Group (MD) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $501.4M, up 1.7% YoY; net income was $47.0M and Adjusted EBITDA was $85.5M, down from $71.7M and $87.3M, respectively.

• 9M revenue was $1.465B vs. $1.420B; Adjusted EBITDA rose to $220.1M from $209.7M, while net income fell to $116.4M from $131.7M.

Financial highlights

• Q3 operating income was $65.2M, down 4.2% YoY; diluted GAAP EPS was $0.59 vs. $0.84, while Adjusted EPS rose to $0.72 from $0.67.

• Q3 revenue growth reflected recent acquisitions net of dispositions and 0.6% same-unit growth; 9M same-unit revenue increased 2.0%.

• 9M operating income was $163.8M vs. $160.0M; Adjusted EPS was $1.78 vs. $1.54, while diluted GAAP EPS was $1.43 vs. $1.54.

• Prior-year Q3 results included a $20.9M net gain on divested-business investments, excluded from Adjusted EBITDA and Adjusted EPS.

Outlook and guidance

• FY 2026 Adjusted EBITDA guidance narrowed to $290M–$300M; management cited flexibility amid volume and pricing variability.

• Operating cash, cash on hand and available credit were expected to fund obligations for at least 12 months from filing issuance; management expected debt-covenant compliance through 2026.

• The Term A Loan matures in February 2027, with a final $171.9M payment due at maturity; 2027 coding-rule effects remain uncertain pending final rules and provider responses.